Barkhof F - Search Results

1

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Barkhof F, et al. Neurology. 2019 Nov 5;93(19):e1778-e1786. doi: 10.1212/WNL.0000000000008189. Epub 2019 Sep 4. Neurology. 2019. PMID: 31484710 Free PMC article. Clinical Trial.

2

A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

Barkhof F, Frequin ST, Hommes OR, Lamers K, Scheltens P, van Geel WJ, Valk J. Barkhof F, et al. Neurology. 1992 Jan;42(1):63-7. doi: 10.1212/wnl.42.1.63. Neurology. 1992. PMID: 1370864

3

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, Hommes OR. Barkhof F, et al. AJR Am J Roentgenol. 1992 Nov;159(5):1041-7. doi: 10.2214/ajr.159.5.1414773. AJR Am J Roentgenol. 1992. PMID: 1414773

4

Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.

Barkhof F, Hommes OR, Scheltens P, Valk J. Barkhof F, et al. Neurology. 1991 Aug;41(8):1219-22. doi: 10.1212/wnl.41.8.1219. Neurology. 1991. PMID: 1866009

5

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Miller DH, et al. Among authors: barkhof f. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):683-8. doi: 10.1136/jnnp.54.8.683. J Neurol Neurosurg Psychiatry. 1991. PMID: 1940938 Free PMC article.

6

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.

van Walderveen MA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin ST, Valk J. van Walderveen MA, et al. Among authors: barkhof f. Neurology. 1995 Sep;45(9):1684-90. doi: 10.1212/wnl.45.9.1684. Neurology. 1995. PMID: 7675227

7

Multiple sclerosis therapy. A practical guide.

van Oosten BW, Truyen L, Barkhof F, Polman CH. van Oosten BW, et al. Among authors: barkhof f. Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005. Drugs. 1995. PMID: 7729328 Review.

8

Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging.

Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W. Scheltens P, et al. Among authors: barkhof f. Neurology. 1995 May;45(5):883-8. doi: 10.1212/wnl.45.5.883. Neurology. 1995. PMID: 7746401

9

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.

Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH. Filippi M, et al. Among authors: barkhof f. Neurology. 1995 Feb;45(2):255-60. doi: 10.1212/wnl.45.2.255. Neurology. 1995. PMID: 7854522 Clinical Trial.

10

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

Barkhof F, Tas MW, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, Valk J. Barkhof F, et al. Neuroradiology. 1994 Jul;36(5):382-7. doi: 10.1007/BF00612124. Neuroradiology. 1994. PMID: 7936181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,515 results

Search Page

Filters